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Abstract: Magnetic iron oxide (IO) nanoparticles with a long blood retention time, 
biodegradability and low toxicity have emerged as one of the primary nanomaterials for bio-
medical applications in vitro and in vivo. IO nanoparticles have a large surface area and can be 
engineered to provide a large number of functional groups for cross-linking to tumor-targeting 
ligands such as monoclonal antibodies, peptides, or small molecules for diagnostic imaging or 
delivery of therapeutic agents. IO nanoparticles possess unique paramagnetic properties, which 
generate signiﬁ  cant susceptibility effects resulting in strong T2 and T*
2 contrast, as well as T1 
effects at very low concentrations for magnetic resonance imaging (MRI), which is widely used 
for clinical oncology imaging. We review recent advances in the development of targeted IO 
nanoparticles for tumor imaging and therapy.
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Introduction
Cancer remains one of the leading causes of death in the world. Despite advances in 
our understanding of molecular and cancer biology, discovery of cancer biomarkers 
and conventional surgical procedures, radiotherapy, and chemotherapy, the overall 
survival rate from cancer has not signiﬁ  cantly improved in the past two decades 
(Jemal et al 2008). The development of novel approaches for early detection and 
cancer marker-speciﬁ  c and personalized treatment of cancers is urgently needed to 
increase patient survival.
Recent advances in nanoscience and nanotechnology have led to the development 
of nanomaterials for molecular and cellular imaging, cancer therapy, and integrated 
nanodevices for cancer detection and screening (Jain 2005; Nie et al 2007; Sengupta 
and Sasisekharan 2007; Wang et al 2007). It is highly desirable that nanoparticles can 
not only provide sensitive and speciﬁ  c imaging information in cancer patients but also 
selectively deliver anticancer drugs to tumor sites. Currently, there is limited knowl-
edge of suitable biomarkers for imaging, selection of the imaging target and contrast 
enhance materials, and the chemistry required to assemble the bioactive imaging probe. 
In addition, numerous obstacles are faced in developing cancer-speciﬁ  c imaging agents, 
such as 1) delivery of the probe to the targeted tissue/tumor; 2) biocompatibility and 
toxicity; 3) stability of the probe and effective signal enhancement in vivo; 4) adequate 
imaging methods and strategies. During chemotherapy, pharmacologically active 
cancer drugs reach the tumor tissue with poor speciﬁ  city and induce dose-limiting 
toxicities. Nanoparticle drug delivery may provide a more efﬁ  cient, less harmful solu-
tion to overcome these problems.
To date, the development of tumor-targeted nanoparticles remains extremely chal-
lenging. Magnetic resonance imaging (MRI) provides superb image resolution and 
exquisite soft tissue contrast for revealing tissue morphology and anatomical details, 
while allowing for whole body imaging of animals and humans. Although MRI has International Journal of Nanomedicine 2008:3(3) 312
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become one of the primary oncology imaging modalities, 
its sensitivity is challenged when applied to molecular and 
cellular imaging (Bradbury and Hricak 2005; Ito 2006). To 
obtain contrast enhancement and signal ampliﬁ  cation, mag-
netic contrast agents are often used. Although gadolinium 
diethylenetriaminopentaacetic acid (Gd-DTPA), which 
shows a strong T1 shortening effect, is widely accepted in 
clinical use, it has relatively low contrast effects and a very 
short retention time in vivo. In addition, the toxicity and 
biocompatibility of gadolinium during and after endocytosis 
by cells are still largely unknown (Bird et al 1988; Bulte and 
Kraitchman 2004; Kim et al 2007). Recently, magnetic iron 
oxide (IO) nanoparticles have emerged as a new generation of 
target-speciﬁ  c MRI T2 contrast agents. Magnetic IO nanopar-
ticles are much more efﬁ  cient than Gd-DTPA as relaxation 
promoters and their magnetic properties can be manipulated 
by controlling the sizes of core and coating surface (Rogers 
and Basu 2005). More importantly, IO nanoparticles have a 
long blood retention time, biodegradability and low toxicity 
(Harisinghani et al 2003; Funovics et al 2004; Jain et al 2005; 
Bradbury and Hricak 2005; Montet et al 2006). In this review, 
we focus on recent advances in the development of targeted 
IO nanoparticles for tumor imaging and therapy.
Production of magnetic iron oxide 
nanoparticles and functionalization 
of the nanoparticle surface
There are many different kinds of chemical methods for 
synthesizing magnetic nanoparticles. The most commonly 
used are precipitation-based approaches, either by coprecipi-
tation or reverse micelle synthesis (Shen et al 1993; Nitin 
et al 2004). IO nanoparticles without any surface coating 
are not stable in aqueous media and readily aggregate and 
precipitate. For in vivo applications, the particles often form 
aggregates in blood and are sequestered by macrophages 
(Lee et al 2006). Therefore, the surface of IO nanoparticles 
should be coated with a variety of different moieties that 
can eliminate or minimize their aggregation under physi-
ological conditions. Usually, two main approaches are used 
for coating magnetic IO nanoparticles, including in situ 
coatings with which the magnetic nanoparticles are coated 
during the synthesis process and post-synthesis coatings 
(Berry et al 2004; Jodin et al 2006; Horak et al 2007). In 
addition, magnetic IO nanoparticles can also be encapsulated 
in liposomes to create magnetoliposomes (De Cuyper and 
Joniau 1988).
The amphiphilic polymeric surfactants such as poloxamers, 
poloxamines and poly(ethylene glycol) (PEG) derivatives are 
usually used for coating the surface of IO nanoparticles, since 
they can minimize or eliminate opsonization of IO nanopar-
ticles. Among them, PEG is the most used chemical material, 
which confers on IO nanoparticles several important proper-
ties such as high solubility and stability in aqueous solutions, 
biocompatibility, and prolonged blood circulation time. More 
importantly, the functional groups of modiﬁ  ed PEG allow 
for bioconjugation of various ligands or therapeutic agents 
to IO nanoparticles (Kohler et al 2004; Mikhaylova et al 
2004; Nitin et al 2004; Gupta and Gupta 2005; Veiseh et al 
2005; Lee et al 2006, 2007a; Kumagai et al 2007). However, 
PEG-coated IO nanoparticles may have limited binding 
sites available for further ligand binding, since the number 
of functional groups on the surface of each IO nanoparticle 
is limited (Gupta and Gupta 2005). Laconte and colleagues 
(2007) reported that the molecular weight of the PEG portion 
of the micelle coating is related to the overall IO nanopar-
ticle diameter, while coating thickness can signiﬁ  cantly 
affect their relaxivity. Our group recently observed that 
the molecular weight of PEG could signiﬁ  cantly affect the 
distribution of PEG-coated IO nanoparticles in vivo. Thus, 
it is critical to select the ratio and molecular weight of PEG 
when designing IO nanoparticle probes for targeted imaging 
and therapy in vivo.
In addition to PEG coating, other materials such as 
antibiofouling poly(TMSMA-r-PEGMA) (Lee et al 2006), 
hyaluronic acid (HA) layers (Kumar et al 2007) and carboxyl-
functionalized poly(amidoamine) (PAMAM) dendrimers 
of generation 3 (G3) (Shi et al 2007) have also been used 
to coat the surface of IO nanoparticles for either increasing 
circulation time in the blood or delivering peptides at high 
efﬁ  ciency.
Recently, we have developed a new class of superpara-
magnetic iron particles that have uniform sizes ranging from 
5–30 nm and can be further functionalized through surface 
coating with amphiphilic triblock polymers, which provide 
functional groups for conjugating tumor-targeting biomol-
ecules such as peptides or antibodies. The triblock polymer 
developed in our group has surface reactivity for introducing 
various or multiple functional groups including the carboxylate 
group that can be used to cross-link “probe molecules” for 
biomarker-targeted speciﬁ  c binding (Gao et al 2004).
Despite signiﬁ  cant efforts in developing MRI contrast 
agents based on IO nanoparticle formulations, several 
obstacles remain to be overcome. The major challenge is to 
develop a surface coating material that can not only stabilize 
the nanoparticle but also provide active functional groups for 
controllable bioconjugation of “probe” ligands. Traditional International Journal of Nanomedicine 2008:3(3) 313
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ligands (eg, dextran) used for the stabilization of magnetic 
nanocrystals often have weak ligand-particle interactions and 
can be easily detached from the surface of the nanocrystals, 
leading to the aggregation of nanoparticles and eventually 
their precipitation under physiological conditions or simply 
during storage times. When further derivatization is needed, 
such a weak interaction between ligand and particle may not 
sustain the required reaction conditions. The magnetism of 
IO nanoparticles and its effect on MR imaging can depend 
signiﬁ  cantly on their morphology, crystal structure, size and 
uniformity. Currently, most studies using IO nanoparticles 
to develop molecular imaging probes utilize commercially 
available formulations such as Ferumoxtran, which offers 
limited control over particle size and morphology, critical to 
the mass magnetization value and potential effect on imaging 
contrast. When speciﬁ  cally considering their use in imag-
ing applications in vivo, IO nanoparticles with small size 
(5–150 nm) and high mass magnetization value are desired, 
in addition to the proposed target speciﬁ  city, for which easy 
conjugation with biomolecules is required. Different sizes 
of IO nanoparticles including SPIO (superparamagnetic 
IO, 60–150 nm), USPIO (ultrasmall SPIO, 10–50 nm), and 
MINO (monocrystalline IO) can lead to different magnetic 
properties and function differently in various applications 
(Wang et al 2001; Thorek et al 2006).
Targeted IO nanoparticles
for tumor imaging
Although the feasibility of using IO nanoparticles for cancer 
detection and drug delivery has been demonstrated (Corot 
et al 2006; Thorek et al 2006), a major obstacle limiting their 
clinical application is that nontumor-targeted nanoparticles 
are unable to reach sufﬁ  cient concentrations in the tumor 
site to either produce a strong signal for tumor imaging or to 
carry optimal amounts of therapeutic agents into tumor cells. 
One approach to overcome this problem is to develop tumor-
targeted IO nanoparticles that are highly sensitive imaging 
probes and/or are capable of conjugating large amounts of 
therapeutic agents (Rhyner et al 2006) (Figure 1).
Development of human cancer is a multistage process 
involving various genetic alterations and cellular abnormali-
ties that provide advantages for growth and progression of 
tumors. Differences in the expression of cellular receptors 
between normal and tumor cells represent a great opportu-
nity for targeting imaging probes to those cellular surface 
molecules.
For engineering tumor targeted-IO nanoparticles, 
different ligands such as antibodies, peptides and small 
molecules targeting the related receptors that are highly 
expressed in tumor cells are usually conjugated to the surface 
of IO nanoparticles. A few studies using targeted IO nanopar-
ticles for tumor imaging have been evaluated in vitro and in 
animal experiments (Table 1).
Antibody-based targeted IO nanoparticles for in vitro 
or in vivo imaging have been studied in several laboratories 
(Cerdan et al 1989; Remsen et al 1996; Tiefenauer et al 
1996; Artemov et al 2003; Funovics et al 2004; Huh et al 
2005; Toma et al 2005; Serda et al 2007) and were found 
to maintain both the properties of the antibody and the 
magnetic particles. Among these studies, conjugation of the 
magnetism-engineered iron oxide (MEIO) nanoparticles 
with Herceptin, a well-known antibody against the HER2/
neu receptor which is overexpressed in breast cancer cells, 
showed in vivo cancer targeting and imaging of HER2/neu 
with high sensitivity which enables the MR detection of 
tumors as small as 50 mg (Lee et al 2007b). Although the 
efﬁ  cacy of monoclonal antibody-targeted IO nanoparticles 
has been demonstrated, the size of antibodies used in these 
studies is very large and is not ideal for efﬁ  cient conjuga-
tion to the surface of IO nanoparticles. The large size of the 
intact antibody also limits the ability of the IO nanoparticle to 
permeate through the vasculature into areas with tumor cells. 
In addition, the interaction of antibody with Fc receptors on 
normal tissues can alter the speciﬁ  city of tumor-targeted 
nanoparticles. To solve those problems, peptides or single 
chain antibodies with small molecular weight can be used 
as target moieties for engineering targeted IO nanoparticles. 
In this review, we describe several recent advances in using 
peptides for tumor imaging.
Peptides that target related receptors on tumor cells surface 
can be internalized via receptor-mediated endocytosis, which 
Liver 
Tumor
Spleen
SPIO
PEG
Targeting ligand
antibody or
small molecules
Figure 1 Targeted IO nanoparticles for tumor imaging in vivo. The tumor-speciﬁ  c 
ligands/antibodies were conjugated to the surface of SPIO coated by PEG. Targeted 
IO nanoparticles accumulate in solid tumor tissue mainly by receptor-mediated 
endocytosis and are usually taken up by macrophages in the liver (Küpffer cells) 
and spleen.International Journal of Nanomedicine 2008:3(3) 314
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Table 1 Targeted iron oxide nanoparticles for tumor imaging
Iron oxide 
nanoparticles
Targeting ligands Targets Tumor Experimental 
conditions
USPIO (Cerdan et al 1989) Monoclonal antibody-610 Surface antigen Colon carcinoma cell lines In vitro
SPIO (Tiefenauer 
et al 1996)
Antibody to carcinoem-
bryonic antigen (CEA)
CEA Colon tumor In vivo
MINO (Remsen 
et al 1996)
Monoclonal antibody L6 Surface antigen Intracranial tumor LX-1 In vivo
USPIO (Kresse et al 1998) Transferrin Transferrin receptor Rat mammary carcinoma In vivo
Streptavidin-conjugated 
SPIO (Artemov et al 2003)
Monoclonal antibody-
Her/Neu
Her-2/neu receptors Breast cancer In vitro
CLIO-NH2 
(Moore et al 2004)
EPPT peptide Underglycosylated 
mucin-1 antigen 
(uMUC-1)
Breast , colon, pancreas 
and lung cancer cell lines
In vivo
Dextran-coated super-
paramagnetic maghemite 
(γ-Fe2O3) nanocrystals 
(Sonvico et al 2005)
Folic acid Folate receptor Human epithelial 
mouth carcinoma
In vitro
Ferumoxides (SPIO) 
(Toma et al 2005)
Monoclonal antibody A7 Colorectal tumor 
antigen
Colorectal carcinoma In vivo
Iron oxide nanocrystals 
(Fe3O4 ) (Huh et al 2005)
Herceptin Her-2/neu receptors NIH3T6.7 In vivo
SPIO (Kohler et al 2005) Methotrexate Folate receptor Human cervical 
cancer cells
In vitro
SPIO (Veiseh et al 2005) Chlorotoxin peptide membrane-bound 
matrixmetallopro-
teinase-2 (MMP-2)
Rat glioma In vitro
Biofunctional PEG-SPIO 
(Sun et al 2006)
Folic acid Folate receptor Human cervical 
cancer cells
In vitro
SPIO encapsulated with 
photodynamic agent 
(Reddy et al 2006)
F3 peptide Surface-localized 
tumor vasculature
Rat glioma In vivo
HFn-IO (Uchida et al2006) RGD4C αvß3 integrins Melanoma cells In vitro
SPIO (Leuschner 
et al 2006)
Luteinizing hormone 
releasing hormone 
(LHRH)
LHRH receptor Breast cancer In vivo
SPIO (Simberg et al 2007) CREKA peptide Clotted plasma 
proteins
Breast cancer In vivo
USPIO (Zhang et al 2007) Arg-Gly-Asp (RGD) αvß3 integrins Human epidermoid 
carcinoma
In vivo
PEG-SPIO 
(Chen et al 2007b)
Folic acid Folate receptor Human epithelial 
mouth carcinoma
In vivo
Streptavidin-SPIO 
(Serda et al 2007)
Antibody to Prostate-
speciﬁ  c membrane 
antigen (PSMA)
PSMA Human prostate 
cancer cells
In vitro
Magnetism-engineered iron 
oxide (MEIO) nanopar-
ticles (Lee et al 2007b)
Herceptin Her-2/neu receptors NIH3T6.7 In vivo
PEG- IO (Sun et al 2008) chlorotoxin membrane-bound 
matrixmetallo  pro-
teinase-2 (MMP-2)
Rat glioma In vivoInternational Journal of Nanomedicine 2008:3(3) 315
Iron oxide nanoparticles for tumor imaging and therapy
will increase the uptake of conjugated IO nanoparticles and 
provide persistent MRI contrast enhancement, therefore, 
such types of peptides are ideal ligands for constructing 
targeted IO nanoparticles for tumor imaging. Chlorotoxin 
(Cltx) is a 36-amino acid peptide that can speciﬁ  cally bind 
to matrix metalloproteinase-2 (MMP-2) on the surface of 
cells. MMP-2 is overexpressed in gliomas and other related 
cancers and degrades the extracellular matrix during can-
cer invasion (Soroceanu et al 1998; Deshane et al 2003; 
Veiseh et al 2007). Sun and colleagues (2008) conjugated 
Cltx to IO nanoparticles with covalently bound bifunctional 
PEG polymer and showed that internalization of the Cltx-
conjugated IO nanoparticles by 9L glioma cells was 10-fold 
higher than that of the nontargeted nanoparticles after 2hrs 
incubation. The R2(1/T2) relaxivity was 5.20mm-1s-1 and 
0.22mm-1s-1 for the tumor cells after incubation with the Cltx-
targeted IO nanoparticles and nontargeted IO nanoparticles, 
respectively. In vivo MRI showed that the tumor contrast 
enhancement in the superimposed R2 change was signiﬁ  -
cantly higher in the mouse injected with Cltx-targeted IO 
nanoparticles than in the mouse receiving the nontargeted 
nanoparticles (Sun et al 2008).
The development of targeted IO nanoparticles for early 
tumor detection remains challenging. Underglycosylated 
mucin-1 antigen (uMUC-1) is an early tumor marker that is 
overexpressed on almost all human epithelial cell adenocarci-
nomas. Some important features render uMUC-1 a promising 
target for tumor imaging, 1) expressed in over 50% of all 
human cancers and remained homogeneously upregulated 
during the life growth of the tumor, 2) underglycosylated 
in tumor tissues but heavily glycosylated in normal tissues, 
make it possible to design probes that discriminate between 
normal and adenocarcinoma cells, 3) ubiquitously expressed 
on the cell surface, making it an accessible target for bind-
ing and imaging. Moore and colleagues (2004) synthesized 
EPPT1 peptide which speciﬁ  cally recognizes uMUC-1 and 
conjugated it to the dextran coat of crosslinked superpara-
magnetic iron oxide nanoparticles (CLIO). As shown in 
Figure 2, 24 hours after injection of targeted CLIO nanopar-
ticles, a signiﬁ  cant T2 signal reduction was observed in some 
regions of uMUC-1-positive LS174T tumors, while no sig-
niﬁ  cant change was seen in uMUC-1-negative U87 tumors. 
In addition, these results were further demonstrated by near-
infrared ﬂ  uorescence (NIRF) imaging. In this study, NIRF 
Cy5.5 dye-labeled CLIO nanoparticles were used both as 
MR- and NIRF-imaging contrast agent. This unique imaging 
probe produced a high-resolution signal on MR images and 
real-time NIRF imaging data, providing comprehensive 
information on tumor localization, environment, and status. 
This agent may have the potential to be applied for early 
tumor detection (Moore et al 2004).
To date, tumor metastasis is still one of the main causes of 
death for breast cancer patients. Approximately 37% of breast 
cancer patients have tumor metastases in the bone and lymph 
nodes at the time of diagnosis, and the 5-year survival rates for 
these patients is only 27% (Jemal et al 2008). Development of 
targeted IO nanoparticles that could be used for the detection of 
early metastasis may improve the 5-year survival rates of breast 
cancer patients. About 52% of human breast cancers express 
binding sites for receptors for luteinizing hormone-releasing 
hormone (LHRH) (Chatzistamou et al 2000). LHRH is a 
decapeptide that has the primary sequence of EHWSYGLRPG. 
LHRH-SPIO nanoparticles speciﬁ  cally accumulated in primary 
tumor cells and metastatic cells through receptor-mediated 
endocytosis, and the concentration of targeted SPIO nanopar-
ticles was 12-fold higher than that of SPIO nanoparticles in 
vitro. In vivo data showed that the expression of LHRH-SPIO 
nanoparticles was 7.5-fold higher in tumors and 11-fold higher 
in lung metastatic cells than that of nontargeted nanoparticles. 
After conjugating LHRH to SPIO nanoparticles, in addition to 
receptor targeting, LHRH may render the nanoparticles neutral, 
further increasing their circulation time and decreasing their 
recognition by the RES in vivo. This study demonstrated that 
LHRH-conjugated SPIO nanoparticles could be used as an 
MRI contrast agent to detect metastatic breast cancer cells in 
vivo with high sensitivity (Leuschner et al 2006). One of the 
interesting results was that LHRH-SPIO nanoparticles were 
found by TEM study to accumulate in the cytosol and the 
nucleus in the breast cancer cells; this may be an advantage for 
delivering drug in the future, since it seems this unique targeted 
IO nanoparticle could escape from the endosome.
Angiogenesis plays a critical role in the development of 
tumors; the αvß3 integrin is a marker of angiogenesis and 
its expression correlates with tumor grade. Therefore, αvß3 
integrin is an ideal target for in vivo tumor imaging since the 
target is present on the surface of the vessels and can directly 
be accessed from the blood. Zhang and colleagues (2007) 
used 3-aminopropyltrimethoxysilane (APTMS) with func-
tional amino groups as a coating material for modiﬁ  cation of 
IO nanoparticles. APTMS can form a very thin monolayer 
on the surface and can be used to covalently attach related 
ligands. The Arg-Gly-Asp (RGD) peptide which binds to the 
αvß3 integrin receptor was conjugated to APTMS-coated 
USPIO nanoparticles. Following systemic administration of 
the RGD-USPIO nanoparticles in nude mice bearing tumors 
with different levels of αvß3 integrin-positive vessels, results International Journal of Nanomedicine 2008:3(3) 316
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showed that RGD-USPIO nanoparticles targeted to the tumor 
vessels and the change in T2 relaxation was related to the 
degree of expression of αvß3 integrin detected by 1.5-T MR 
scanner (Zhang et al 2007).
To increase the sensitivity of in vivo tumor imaging of 
nanoparticles, it is necessary to deliver large amounts of 
the nanoparticles not only into the tumor cells but also to 
a tumor mass. Most of the currently used target molecules, 
such as Her-2/neu, αvß3 integrin, PMSA and MUC-1, are 
expressed in subpopulations of tumor tissues or speciﬁ  c 
tumor types. Recently, Simberg and colleagues (2007) syn-
thesized the tumor-homing peptide CREKA (Cys-Arg-Glu-
Lys-Ala), which can form a distinct meshwork in the tumor 
stroma speciﬁ  cally. A CREKA-conjugated nanoparticle 
accumulated in both tumor vessels and stroma, resulting in 
intravascular clotting in tumor blood vessels which attracted 
more nanoparticles into the tumor, amplifying the targeting. 
There are several advantages of such targeted-SPIO nanopar-
ticles, 1) high speciﬁ  city for tumor homing, 2) enhanced MR 
imaging in tumor, 3) physical blockade of tumor vessels 
by local embolism. The clotting caused by CREKA-SPIO 
nanoparticles in tumor vessels may improve tumor detection 
by optical imaging techniques. Another potential application 
of the nanoparticle is for constructing drug delivery nanopar-
ticles which can deliver drugs in tumor vessels and slowly 
release them (Simberg et al 2007).
The low molecular weight vitamin folic acid (FA), whose 
receptor is overexpressed on the surface of many human 
tumor cells, has been studied as a targeting agent. The advan-
tages of using FA as a targeting ligand for tumor imaging 
include: 1) relatively higher binding afﬁ  nity for its receptor 
(κd = 10−10 M), 2) low cost, easy conjugation with both thera-
peutic and imaging agents, 3) compatibility in both organic 
and aqueous solvents, 4) lack of immunogenicity (Low et al 
2008). Sun and colleagues (2006) used heterobifunctional 
PEG 600 to coat the surface of IO nanoparticles and subse-
quently attached FA to the nanoparticles through an amide 
linkage at the free terminus of PEG. Their results showed 
that folate receptor-positive human cervical carcinoma HeLa 
cells took up about 12-fold more FA-IO nanoparticles than 
nontargeted IO nanoparticles (Sun et al 2006). One recent 
study showed by MRI that SPIO-PEG-FA could target human 
nasopharyngeal epidermoid carcinoma (KB) cells both in 
vitro and in vivo (Chen et al 2007).
In vivo tumor imaging with MRI requires the delivery 
of sufﬁ  cient concentrations of IO nanoparticles. Pinkernelle 
and colleagues (2005) reported that single IO nanoparticle-
labeled human colon carcinoma cells can be detected using 
MRI techniques in vitro, the lowest concentration of iron 
needed is about 4–5 μg/106 cells (Pinkernelle et al 2005). For 
imaging by targeted IO nanoparticles, the sensitivity depends 
on the target concentrations in tumor cells, for example, 
some targets are often quite weakly expressed (104 folate 
receptors in brain glioma cells) (Saul et al 2003) while others 
are very highly expressed (3 × 106 epidermal growth factor 
receptors in A431 human squamous carcinoma cells) (Jinno 
et al 1996). In addition, the targeting of IO nanoparticles to 
cells depends on a number of factors including extracellular 
IO nanoparticle concentration, particle size, surface coating, 
and incubation time.
There remain many problems to be addressed in the study 
of IO nanoparticles for tumor imaging, including 1) the 
optimal number of targeted ligands on IO nanoparticles 
must be investigated and determined in each application, 
since excessive amounts of targeting ligands on the IO 
nanoparticles may not necessarily increase binding of the 
IO nanoparticles to speciﬁ  c cells, but can increase the size 
of the nanoparticles and further affect the R2 characteristics. 
The ideal ratio of ligands and IO nanoparticles may be depen-
dent on the number of receptors on targeted cells, the binding 
afﬁ  nity of ligands to receptors and the molecular weight and 
size of ligands, 2) the fate of targeted IO nanoparticles after 
cell internalization is still controversial, with most reports 
showing that nanoparticles enter into endosomes and are then 
degraded in lysosomes, while other studies have shown that 
they can escape from the endosome and locate in the cyto-
plasm or around the nucleus. It seems that conjugated ligands 
and surface coating affect the distribution of particles within 
the cells, 3) the range of the concentration of IO nanoparticles 
used for animal studies is large, from 1 mg to 250 mg of 
Fe/kg, making it difﬁ  cult to compare results from different 
research groups, 4) the quantiﬁ  cation of IO nanoparticle 
levels in vivo is still a challenge. In this case, MRI can be 
combined with other speciﬁ  c labeling technologies such as 
radio- and NIR-labeling, which may offer the possibility of 
multimodal imaging for measuring the biodistribution of 
targeted IO nanoparticles.
Strategies to increase sensitivity 
and speciﬁ  city of targeted IO 
nanoparticles for in vivo imaging
Although recent advances have demonstrated the feasibility 
of using targeted IO nanoparticles for noninvasive imag-
ing in animal models, one of the main problems is that IO 
nanoparticles are usually taken up by macrophages in the 
liver (Küpffer cells), spleen and bone marrow, thus affecting International Journal of Nanomedicine 2008:3(3) 317
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their speciﬁ  city and sensitivity and rendering them less than 
ideal for this application. Previous studies have reported 
the uptake of dextran-coated monocrystalline iron oxide 
nanoparticles (MION) ranging from 0.011 to 0.118 pg of 
iron per cell (1 hr of incubation) by various tumor cells, and 
a maximum load of 0.97 pg in mouse macrophages (Moore 
et al 1997). A biodistribution study of MnMEIO-Herceptin 
conjugates labeled with radioactive 111In by γ-counter analy-
ses showed that in addition to being distributed in the tumor 
(3.4% injected dose (ID)/g), nanoparticles were also found 
in the liver (12.8% ID/g), spleen (8.7% ID/g) and muscle 
(1.0% ID/g) (Lee et al 2007b).
Macrophages are capable of internalizing a wide variety 
of materials including iron oxide nanoparticles. There are 
many different pathways that can regulate the internaliza-
tion of IO nanoparticles by macrophage cells because of the 
diversity in particle size, tendency to aggregate and surface 
coating. Several studies have sought to minimize the non-
speciﬁ  c uptake of IO nanoparticles by macrophages (Zhang 
et al 2002; Rogers and Basu 2005; Leuschner et al 2006; 
Lee et al 2006).
Rogers and Basu (2005) reported that pretreatment 
of macrophages with the MG-CoA reductase inhibitor 
lovastatin (1μM) could signiﬁ  cantly reduce SPIO uptake by 
activated macrophages to 61% of untreated cells. Lovastatin 
downregulates class A types I and II macrophage scavenger 
receptors, and may bind to other related receptors in 
macrophages and reduce receptor recycling, thus partially 
abolishing IO internalization. The uptake rates of IO 
nanoparticles by liver and spleen can be decreased by limiting 
phagocytosis, leading to longer blood half-lives which provide 
favorable conditions for nanoparticles to reach their targets. 
Pretreatment with lovastatin before the injection of targeted 
IO nanoparticles may provide a new method to decrease 
the nonspeciﬁ  c uptake of targeted IO nanoparticles by the 
liver or spleen but increase their concentration in the tumor 
site (Rogers and Basu 2005). Another method to decrease 
nonspeciﬁ  c uptake of IO nanoparticles is to eliminate plasma 
opsonins by injecting decoy particles. Simberg and colleagues 
(2007) found that this treatment caused 5-fold prolongation 
in particle half-life and that Ni-liposome pretreatment greatly 
increased tumor homing of the nanoparticles, which primarily 
localized in tumor blood vessels. However, toxicity limits the 
further application of this agent.
In general, positively charged nontargeted IO nanopar-
ticles bind to cells through electrostatic interaction with the 
negatively charged cell membranes and are then internalized 
by cells, while endocytosis of negatively surface-charged 
IO nanoparticles may occur through both protein-mediated 
phagocytosis and diffusion. A change in IO nanoparticle 
surface charge can be induced by covalently coupling dif-
ferent chemical materials such as amino, PEG and carboxyl 
groups. It has been reported that albumin-IO nanoparticles 
with a neutral charge showed a reduced phagocytic uptake 
in comparison with negatively or positively charged particles 
(Roser et al 1998). Fang and colleagues (2006) found that 
the charge of nanoparticles strongly affects both the blood 
circulation time and the bioavailability of particles within 
the body. The surface charge of IO particles should ideally 
be maintained at neutral or close to neutral for imaging and 
drug delivery (Shi et al 2007).
In addition, the size of IO nanoparticles will potentially 
affect their distribution in vivo. Intravenously injected 
nanoparticles with diameters greater than 200 nm are usually 
taken up by the liver and spleen, and are eventually removed 
by the cells of the RES, resulting in decreased blood circula-
tion times (Remsen et al 1996). Smaller particles with diam-
eters less than 5 nm are rapidly removed through the kidney 
(Gupta and Gupta 2005), therefore, IO nanoparticles ranging 
from 5 to 150 nm may offer the most effective distribution 
in certain tissues, especially in tumors.
To develop tumor targeted-IO nanoparticles that have 
both high sensitivity and speciﬁ  city remains challenging. 
Despite many recent advances in the development of targeted 
IO nanoparticles for tumor imaging, we are still limited in our 
ability to detect tumors at their early stages of development, 
to monitor their invasion and metastasis and to assess their 
responses to therapy.
Tumor-targeted IO nanoparticles 
as selective drug delivery vehicles
Targeted IO nanoparticles can be used to treat tumors in 
three different ways. Firstly, speciﬁ  c antibodies can be 
conjugated to the IO nanoparticles to selectively bind 
to related receptors and inhibit tumor growth (Huh et al 
2005). Secondly, targeted IO nanoparticles can be used 
for hyperthermia for tumor therapy (DeNardo et al 2005; 
Sonvico et al 2005; Jordan et al 2006). Thirdly, drugs can 
be loaded onto the IO nanoparticles for targeted therapy. In 
this review, we focus on selective drug delivery by targeted 
IO nanoparticles.
Increasing evidence shows that the selective delivery of 
therapeutic agents into a tumor mass may minimize toxicity 
to normal tissues and improve bioavailability of cytotoxic 
agents (Shenoy et al 2005; Gang et al 2007; Bae et al 2007; 
Lee et al 2007c).International Journal of Nanomedicine 2008:3(3) 318
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There are several strategies to incorporate drugs into 
targeted IO nanoparticles. Drugs can be linked to the carrier 
coating, deposited in the surface layer, or trapped within the 
IO nanoparticles themselves (Chen et al 2007). They can be 
released by diffusion, vehicle rupture, dissolution or endo-
cystosis of the formulation (Lanza et al 2004; Atri 2006). The 
imaging signals produced by IO nanoparticles detected by 
MRI combined with the amount of speciﬁ  c drug contained 
per particle can be used to estimate the tissue drug levels. In 
addition, radio- or organic dye-labeled drugs can be loaded 
into the IO nanoparticles for more accurate quantiﬁ  cation of 
drug distribution in vivo.
Unfortunately, only a few studies have used targeted IO 
nanoparticles as drug delivery carriers, especially for in vivo 
applications. Methotrexate (MTX) is an analogue of FA, 
which can exhibit both a targeting role as FA and a therapeutic 
effect in cancer cells that overexpress folate receptor on their 
surface. Kohler and colleagues (2005) conjugated MTX to 
IO nanoparticles through amidation between the carboxylic 
acid end groups on MTX and the amine groups on the 
particle surface. Their results showed that cells expressing 
the human folate receptor internalized a higher level of 
MTX-IO nanoparticles than negative control cells. This 
MTX-conjugated IO nanoparticle has several advantages, 
1) high drug loading efﬁ  ciency, the average number of MTX 
molecules per IO nanoparticle with a 10 nm diameter was 
about 418.9, 2) selective internalization of the targeted IO 
nanoparticles in tumor cells overexpressing the folate receptor, 
3) MTX released only from the IO nanoparticles within 
lysosomes inside the targeted cells at low pH by cleavage of 
the amide, 4) drug delivery to the tumor sites may be monitored 
in vivo by MRI in real-time (Kohler et al 2005).
Polymeric micelles are self-assembled nanoparticles from 
amphiphilic block copolymers, which have unique charac-
teristics such as high water-solubility, high drug loading 
capacity and low toxicity. Nasongkla and colleagues (2006) 
developed novel multifunctional polymeric micelles by load-
ing SPIO nanoparticles inside the micelles at 6.7 w/w %. 
The chemotherapeutic agent doxorubicin (DOXO) was also 
loaded at 2.7 w/w % in the micelles and could be released 
through a pH-dependent mechanism. One of the advantages 
of the multifunctional nanoparticles is that the encapsulation 
of DOXO and SPIO nanoparticles inside the hydrophobic 
micelle cores can avoid potential exposure of hydrophobic 
SPIO surfaces and adsorption of blood proteins, thus decreas-
ing nonspeciﬁ  c uptake by RES. In addition, the cRGD ligand 
that can target αvß3 integrins on tumor endothelial cells was 
attached to the micelle surface via a covalent thiol-maleimide 
linkage. Once internalized by targeted cells, high concentra-
tions of DOXO were released in cell nuclei. This integrated 
nanomedicine platform may be an ideal contrast agent for 
targeted tumor therapy and noninvasive imaging in vivo 
(Nasongkla et al 2006).
Yang and colleagues (2007) developed a new multifunc-
tional hybrid nanosystem by combining magnetic nano-
crystals, anticancer drugs and biodegradable amphiphilic 
block copolymers. In this study, there were about 41.7 wt% 
(MnFe2O4) and 40.9wt% (Fe3O4) magnetic nanoparticles 
in the multifunctional magneto-polymeric nanohybrids 
(MMPNs), and the amount of DOXO in the HER-MMPNs 
and entrapment efﬁ  ciency were 3.3 wt% and 71.4%, respec-
tively. In addition, anti-HER antibody was conjugated to 
the MMPNs by utilizing the carboxyl group on the surface 
of the particles. As shown in Figure 3, the injected HER-
MMPNs were delivered in a target-specific manner to 
overexpressed HER2/neu receptors on NIH3T6.7 cells in 
vivo and were taken up by a receptor-mediated endocytosis 
process. The HER-conjugated MMPNs showed signiﬁ  cant 
synergistic effects on inhibition of tumor growth by DOXO. 
The antibody-conjugated nanoparticles also demonstrated 
ultrasensitive targeted detection by MRI in both in vitro and 
in vivo models (Yang et al 2007).
However, there are still many obstacles for successfully 
using tumor-targeted IO nanoparticles as drug carriers in 
vivo, 1) functional group modiﬁ  cation of the drugs during 
conjugation may change their chemical properties, 2) lower 
drug loading efﬁ  ciency, 3) quick release of conjugated 
or encapsulated drugs from IO nanoparticles in the blood 
before entering into tumor mass, 4) drugs usually released in 
the endosome or lysosome but not in the cytoplasm within 
targeting cells, 5) embedding part of the ligand binding site 
in IO nanoparticles may decrease the targeting ability, 6) loss 
in magnetization of the core magnetic material during multi-
step chemical reaction (Jain et al 2005). IO nanoparticles 
combined with other nanoparticles such as biodegradable and 
biocompatible polymeric micelles may overcome some of the 
above obstacles. Proper surface coating of IO nanoparticles 
and methods for the more effective loading of anticancer 
drugs will facilitate drug release proﬁ  les.
Conclusions
Although recent advances have demonstrated the feasibil-
ity of using targeted magnetic IO nanoparticles for tumor 
imaging and therapy, methods and strategies to produce 
tumor-targeted imaging probes with a high specificity 
and sensitivity are still greatly needed. There are many International Journal of Nanomedicine 2008:3(3) 319
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obstacles encountered to the in vivo application of targeted 
magnetic IO nanoparticles for tumor imaging, including 
heterogeneous expression levels of the targeted receptor in 
human tumor cells, various physiological barriers preventing 
the nanoparticle from reaching the targeted cells, and a lack 
of information on the intratumoral distribution and imaging 
capability of targeted nanoparticles within tumor sites that 
are relevant to the locations of most human primary and 
metastatic tumors.
For tumor-targeted therapy, methods to increase the 
loading capacity of anticancer drugs in the nanoparticles and 
control their release at target cells remain quite challenging. 
Since IO particles have been used in clinical settings for many 
years, there is a high potential that these targeted probes will 
be applicable in clinical applications in the future.
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